# First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

Source: https://onco.cc/trials/nct06795022/  
OnCo record `nct06795022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD9793 in hepatocellular carcinoma, run by AstraZeneca, now recruiting.

## Summary

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours is a phase 1/2 interventional study registered as NCT06795022 by AstraZeneca, with 304 participants planned, started 2025-03-27 and due to reach its primary completion in 2027-06-30. Interventions recorded: AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06795022
- Phase: 1/2
- Setting: A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)
- Sponsor: AstraZeneca
- Enrolled: 304

## Sources

- ClinicalTrials.gov NCT06795022: https://clinicaltrials.gov/study/NCT06795022

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [AZD9793](https://onco.cc/drugs/azd9793/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06795022.json